<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362127</url>
  </required_header>
  <id_info>
    <org_study_id>EU-nr 2006-001785-16</org_study_id>
    <secondary_id>2006-001785-16</secondary_id>
    <nct_id>NCT01362127</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia</brief_title>
  <acronym>NeoRes</acronym>
  <official_title>Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Umeå</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malarhospital Eskilstuna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized study is to clarify if neoadjuvant radiochemotherapy gives a
      higher degree of complete histological response than neoadjuvant chemotherapy before surgery
      in patients undergoing treatment for cancer of the esophagus or cardia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether radiochemotherapy gives higher complete histological response (pCR) after resection than chemotherapy alone in patients with resectable carcinoma of the esophagus and cardia.</measure>
    <time_frame>Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of respective neoadjuvant therapies.</measure>
    <time_frame>Three years follow up</time_frame>
    <description>To assess the safety profile of carrying out radical surgery after respective neoadjuvant therapy.
To study the overall and disease free survival in respective groups. To evaluate if pretreatment tumor characteristics predict the pCR and oncomplete pCR rates.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Adenocarcinoma of the Esophagus and Gastric Cardia</condition>
  <arm_group>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiochemotherapy + Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy + surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Suffering moderate/severe hearing impairment and/or tinnitus cisplatin can be replaced. If adenocarcinoma oxaliplatin.If squamos cell carcinoma carboplatin.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.</description>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Suffering moderate/severe hearing impairment and/or tinnitus cisplatin can be replaced. If adenocarcinoma oxaliplatin.If squamos cell carcinoma carboplatin.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified squamos cell carcinoma, adenocarcinoma of the esopohagus or
             gastric cardia (type II)

          -  Tumor located in cervical oesophagus, not requiring laryngo-esophagectomy. Patients
             with performance status 0-1 axxording to WHO scale and with resectable tumours, as
             assessed at the prerandomisation evaluation

          -  Adequate haemotological function, defined as having WBC &gt; 3 x 10(9)/litre and
             platelets &gt; 100 x 10 (9)/litre.

          -  Adequate renal function defined as having normal serum creatinine level and/or
             calculated glomerular filtration rate &gt; 60 ml/min.

          -  Tumour stage: T1Ni, T2N0, T2N1, T3N0, T3N1, M1a

        Exclusion Criteria:

          -  Pregnancy and/or lactation. Women of childbearing ages can be included and provided
             that adequate contraceptive methods are used

          -  Patients with diabetes complications (e.g. rethinopathy, neuropathy) as well as
             patients with uncontrolled cardiac disease or myocard infarction within 12 months are
             considered unsuitable for chemoradiotherapy.

          -  Concomitant malignancy (&lt; 5 years since diagnosis) that can interfere the
             interpretation of study results, ongoing antitumoral treatment.

          -  Patients being unable tom comply with the protocol

          -  Tumor stage T1 N0, T4 NX or TXNXM1b
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Nilsson, AssProfessor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital, Gastrocentrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Lundell, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hospital, Gastrocentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastrocentrum. Department of surgery, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Magnus Nilsson</investigator_full_name>
    <investigator_title>Ass Professor</investigator_title>
  </responsible_party>
  <keyword>Histologically confirmed squamos cell carcinoma or adenocarcinoma of the esophagus and gastric cardia.Suitable for surgery.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

